analytical standard comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-10-07. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
== Research == In April 2014, the American Academy of Neurology found evidence supporting the effectiveness of the cannabis extracts in treating certain symptoms of multiple sclerosis and pain, but there was insufficient evidence to determine effectiveness for treating several other neurological diseases. A 2015 review confirmed that medical marijuana was effective for treating spasticity and chronic pain, but caused numerous short-lasting adverse events, such as dizziness.
== Classic geometries == These are some of the classic geometries from mass spectrographs which are often used to distinguish different types of sector arrangements, although most current instruments do not fit precisely into any of these categories as the designs have evolved further.
=== Intravesical instillation === Sodium hyaluronate can be instilled into the bladder for the treatment of various forms of cystitis and associated bladder pain, by replenishing the glycosaminoglycan layer of the bladder urothelium.
=== Age === Historically, obesity primarily affected adults, but childhood obesity has grown significantly in recent decades. From the mid-1980s to the mid-2010s, obesity roughly doubled among U.S. children ages 2 to 5 and roughly tripled among young people over the age of 6. Overall, obesity in the United States peaks during the middle aged years. During the period 2015–16, the prevalence of obesity among adults aged 20–39 was 35.7%, among those aged 40–59, 42.8%, and among those 60 and over, 41.0%.
Sources: en.wikipedia.org
Bacteria resist phage infection through restriction modification systems that degrade foreign DNA and a system that uses CRISPR sequences to retain fragments of the genomes of phage that the bacteria have come into contact with in the past, which allows them to block virus replication through a form of RNA interference. Third, bacteria can transfer genetic material through direct cell contact via conjugation. In ordinary circumstances, transduction, conjugation, and transformation involve transfer of DNA between individual bacteria of the same species, but occasionally transfer may occur between individuals of different bacterial species, and this may have significant consequences, such as the transfer of antibiotic resistance. In such cases, gene acquisition from other bacteria or the environment is called horizontal gene transfer and may be common under natural conditions.
Paper chromatography is an analytical method used to separate colored chemicals or substances. It can also be used for colorless chemicals that can be located by a stain or other visualisation method after separation. It is now primarily used as a teaching tool, having been replaced in the laboratory by other chromatography methods such as thin-layer chromatography (TLC). This analytic method has three components, a mobile phase, stationary phase and a support medium (the paper). The mobile phase is generally a non-polar organic solvent in which the sample is dissolved. The stationary phase consists of (polar) water molecules that were incorporated into the paper when it was manufactured. The mobile phase travels up the stationary phase by capillary action, carrying the sample with it. The difference between TLC and paper chromatography is that the stationary phase in TLC is a layer of adsorbent (usually silica gel, or aluminium oxide), and the stationary phase in paper chromatography is less absorbent paper. A paper chromatography variant, two-dimensional chromatography, involves using two solvents and rotating the paper 90° in between. This is useful for separating complex mixtures of compounds having similar polarity, for example, amino acids.
Fungaria are distinct from culture collections, which maintain living fungal isolates rather than dried reference specimens. In practice, the two are complementary, and a living culture is often linked to a dried voucher or other reference specimen preserved in a herbarium. The term refers not only to the physical collection but also to the curated metadata associated with each specimen, including information such as taxonomy, substrate, sampling location, and collection date. Because of long-standing practice in mycological nomenclature, fungaria may also include fungus-like organisms that are not classified as fungi under modern systems, such as oomycetes and slime moulds.
HITS-CLIP (High-throughput sequencing of RNA isolated by crosslinking immunoprecipitation or CLIP-seq) PAR-CLIP (Photoactivatable ribonucleoside-enhanced cross-linking and immunoprecipitation) iCLIP (Individual nucleotide-resolution cross-linking and immunoprecipitation) eCLIP (Enhanced cross-linking and immunoprecipitation followed by high-throughput sequencing) sCLIP (Simple cross-linking and immunoprecipitation)
=== Moritz-Hunter Bauer === Moritz-Hunter Bauer (Sid Phoenix) is the heir to the Austrian banking family behind IBN Bauer, with which Tender pursues a merger. He raises objections to the deal on data privacy and regulatory grounds, prompting Henry Muck and Whitney Halberstram, Tender's CEO and CFO respectively, to visit his family's castle in Vienna along with Yasmin to negotiate with him. Although Moritz presents his concerns as principled scrutiny, his views increasingly take on fascist overtones: he articulates a critique of liberal democracy and free-market capitalism and instead expresses admiration for authoritarian models of governance, citing Louis XIV as a political inspiration. He also makes an antisemitic insinuation at Whitney during dinner. Henry and Whitney decide not to continue engaging with him, but Yasmin makes a deal with Princess Johanna Bauer, Moritz's mother, to publish Moritz's views in one of Lord Norton's papers in exchange for his backing the merger. The next day, Moritz's article outlining his views, "The Case for a Benevolent Dictatorship", is published in a national column. Moritz and Johanna later attend Yasmin's fundraiser dinner in Paris for far-right MP Sebastian Stefanowicz. The two are seated beside Harper, to whom they make several racist innuendos.
Sources: en.wikipedia.org
In 2006, sales of Guinness in Ireland and the United Kingdom declined 7 percent. Despite this, Guinness still accounts for more than a quarter of all beer sold in Ireland. By 2015, sales were on the rise in Ireland but flat globally. By 2023, Guinness had grown to become the most popular draught beer in the United Kingdom, with about 11% of all sales. Guinness began retailing in India in 2007. Guinness has a significant share of the African beer market, where it has been sold since 1827. About 40 percent of worldwide total Guinness volume is brewed and sold in Africa, with Foreign Extra Stout the most popular variant. Three of the five Guinness-owned breweries worldwide are located in Africa. The beer is brewed under licence internationally in several countries, including Nigeria, the Bahamas, Canada, Cameroon, Kenya, Uganda, South Korea, Namibia, and Indonesia. In 2017, Guinness teamed up with AB InBev to distribute Guinness in mainland China. China is the single biggest worldwide alcohol market, especially for imported craft beers like Guinness. In 2025, AB InBev started brewing Guinness under licence in China. Initial reception was not favourable, with one publican reportedly stating that the "feedback from everyone is that it tastes like cigarettes or an ashtray. The taste is not the same at all and the aftertaste is terrible". In November 2025, Diego announced a "double-digit" decline in sales in China. The United Kingdom is the only sovereign state to consume more Guinness than Ireland.
January 14 The Senate is unable to pass a resolution which would bar the president from taking further military action in Venezuela without congressional approval after two Republicans switch their initial vote. A Verizon outage affects at least 175,000 people. January 17 – Trump confirms that European countries will be hit with a 10% tariff on "all or any goods" exported to the US from February 1, amid the dispute over Greenland. January 19 – The Indiana Hoosiers defeat the Miami Hurricanes 27–21 in the 2026 College Football Playoff National Championship, winning their first national title. January 20 – DHS launches "Operation Catch of the Day", a surge in immigration enforcement in Maine, primarily in the cities of Lewiston and Portland.
Cells of one type may release the 5(S)-HETE that they make to nearby cells of a second type which then oxidize the 5(S)-HETE to 5-oxo-ETE. This transcellular production typically involves the limited variety of cell types that express active 5-lipoxygenase, lack HEDH activity because of their high levels of NADPH compared to NADP+ levels, and therefore accumulate 5(S)-HETE, not 5-oxo-ETE, upon stimulation. This 5(S)-ETE can leave these cells, enter various cell types that possess 5-HEDH activity along with lower NADPH to NADP+ levels, and thereby be converted to 5-oxo-ETE. Transcellular production of 5-oxo-eicosatetraenoates has been demonstrated in vitro with human neutrophils as the 5(S)-HETE producing cells and human PC-3 prostate cancer cells, platelets, and monocyte-derived dendritic cells as the oxidizing cells. It is theorized that this transcellular metabolism occurs in vivo and provides a mechanism for controlling 5-oxo-ETE production by allowing it to occur or be augmented at sites were 5-lipoxygenase-containing cells congregate with cell types possessing 5-HEDH and favorable NADPH/NADP+ ratios; such sites, it is theorized, might include those involving allergy, inflammation, oxidative stress, and rapidly growing cancers.
The double helix is the dominant tertiary structure for biological DNA, and is also a possible structure for RNA. Three DNA conformations are believed to be found in nature, A-DNA, B-DNA, and Z-DNA. The "B" form described by James D. Watson and Francis Crick is believed to predominate in cells. James D. Watson and Francis Crick described this structure as a double helix with a radius of 10 Å and pitch of 34 Å, making one complete turn about its axis every 10 bp of sequence. The double helix makes one complete turn about its axis every 10.4–10.5 base pairs in solution. This frequency of twist (known as the helical pitch) depends largely on stacking forces that each base exerts on its neighbours in the chain. Double-helical RNA adopts a conformation similar to the A-form structure. Other conformations are possible; in fact, only the letters F, Q, U, V, and Y are now available to describe any new DNA structure that may appear in the future. However, most of these forms have been created synthetically and have not been observed in naturally occurring biological systems.
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.